Rob C. Roovers
Utrecht, UT 3584CM, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Structural insights into the role and targeting of EGFRvIII.
Journal: Structure (London, England : 1993)
Published: November 03, 2023
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
Journal: Cancer immunology research
Published: February 27, 2023
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Journal: Cell reports. Medicine
Published: August 14, 2022
Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.
Journal: Scientific reports
Published: February 03, 2022
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
Journal: Nature cancer
Published: August 10, 2020
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.
Journal: Cancer immunology research
Published: February 13, 2020
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.
Journal: Expert opinion on biological therapy
Published: July 10, 2019
The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers.
Journal: Nature communications
Published: May 03, 2018
Last Updated: 09/26/2026